Avid Bioservices Inc (CDMO)

[cjgaddy]

Known Upcoming Events

Jan17-20: Phacilitate's Immunotherapy World Conf., Miami http://tinyurl.com/zzdbzst
...Jan18 12:30-12:45pm: Steve King (CEO), “Turning up the Heat: PS-Targeting Antibodies Modulate the Tumor Microenvironment & Enhance Checkpoint Blockade”

Jan24-26/Avid/Table#22: WCBP’17: 21st Symposium on Interface of Reg. & Analytical Sciences, WashDC http://www.casss.org/page/WCBP1700 (Theme: “Convergence & Harmonization”)

Feb6-7: GTCbio’s Immunotherapeutics & Immunomonitoring Conf., SanDiego
https://www.gtcbio.com/conferences/immunotherapeutics-immunomonitoring-overview
...AGENDA: http://tinyurl.com/gmrlupq
...Feb7 2:05pm: Dr. Bruce Freimark(Res.Dir./Preclin.Oncology), “Blockade of PS Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Induction of Adaptive Immune Responses Mechanism”

Feb20-22: CHI’s 5th Translational Models in Oncology & I-O, SanFran http://www.triconference.com/Pre-Clinical-Oncology-Models
...Feb21 11:15-11:45am: Michael Gray(Sr.Res.Sci.), “Blockade of PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”

~Mar8: FY'17Q3 (qe 1-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm

??Apr1-5: AACR 2017, WashDC http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105

Apr10-12: Immune Profiling World Congress 2017, WashDC (part of “World Vaccine Congress 2017”) http://tinyurl.com/zlr5cyj
...4-11-17 12:10pm: Dr. Jeff Hutchins***(VP/PreClinRes.), “Increasing the Benefits of Immune Checkpoint Therapies Thru Increased Tumor Infiltrating Activated T-Cells”
***Note: 1-4-17: Dr. Hutchins left Peregrine to become CSO of Heat-Biologics.

??Jun2-6: ASCO 2017, Chicago https://am.asco.org

June12-17: CHI’s 2nd Annual Immunotherapy & Combinations Conf., Boston http://www.worldpreclinicalcongress.com/Cancer-Immunotherapy-Combinations
...Dr. Jeff Hutchins***(VP/PreClinRes.): “Expansion & Activation of T-Cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”
***Note: 1-4-17: Dr. Hutchins left Peregrine to become CSO of Heat-Biologics.

~Jul13: FY'17Q4 (fye 4-30-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm